Camurus and Braeburn Pharmaceuticals have entered into an exclusive license agreement for Camurus’ weekly and monthly subcutaneous buprenorphine injection products (CAM2038) for the treatment of opioid addiction and pain.
Braeburn obtains exclusive rights in North America and option rights in Japan, Korea, Taiwan and China, while Camurus retains all rights in the rest of the world.
Under the agreement, Camurus receives an upfront license fee of $20 million, as well as $35 million and $21 million in development milestones for opioid dependence and pain, respectively.
Camurus is also eligible to mid-teen royalties on Braeburn product sales and can receive up to an additional $75 million in sales milestones.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends